Friday, 29 June 2012

Glycominds - Product Pipeline Analysis

Glycominds Ltd. (GML), a medical device provider, based in Israel. It develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market. The company’s products include gMS DX, gMS Pro EDSS and IBDX. Its gMS Dx test provides clinically valuable information clinicians can use to help make decisions about the likelihood of having Multiple Sclerosis. Glycominds’ technology platform assesses the immune response by measuring the level of antibody biomarkers against glycans. The company’s gMS tests help physicians identify patients who have Multiple Sclerosis and which of these patients are likely to progress towards disability. GML is headquartered in Lod, Israel.

This report is a source for data, analysis and actionable intelligence on the Glycominds portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.